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Abstract
The therapeutic efficacy of anthracyclines relies, at least partially, on the induction of a dendritic One of the most critical processes for the initiation of an immune response against cancer cells succumbing to anthracyclines is the secretion of ATP (8) . Extracellular ATP indeed operates not only as a potent chemotactic signal (by binding to purinergic P2Y2 receptors) (9) , but also as a pro-inflammatory agent, stimulating the activation of the NLRP3 inflammasome (by binding to purinergic P2RX7 receptors) and hence the release of IL-1β (10) . In line with this notion, ATP is essential for the accumulation of monocytic precursors within the tumor bed as well as for their local differentiation into DC-like APCs (3). Thus, shortly (24-72 hours) after the administration of immunogenic chemotherapy (11) (12) (13) , ATP levels increase in the tumor interstitium as a consequence of apoptotic demise of cancer cells. Of note, autophagy is required for such an immunogenic cell death-associated release of ATP to be optimal (8) . Myeloid and lymphoid cells indeed are not recruited by anthracycline-treated autophagy-deficient tumors, correlating with the absence of anticancer immune responses and hence with therapeutic failure (8) . Along similar lines, cancers can be rendered virtually insensitive to the antineoplastic effects of anthracyclines by the overexpression of CD39, a cell surface ATP-degrading enzyme (8) . Besides ATP, other chemotactic factors including multiple chemokines are known to participate into the recruitment of innate and cognate immune effectors to inflammation sites (14) . However, the precise contribution of chemokines to anticancer immune responses elicited by immunogenic chemotherapeutics has not yet been established.
Driven by these premises and incognita, we investigated whether the APCs that accumulate within neoplastic lesions in response to anthracycline-based chemotherapy derive from local precursors or are recruited from external sources and to which extent chemokines regulate their biogenesis. We found that DC-like APCs are freshly recruited into the tumor bed in response to immunogenic chemotherapy and that the host-derived chemokine Ccl2 plays a major, ATPindependent role in this process. In line with this notion, Ccl2 and its major receptor, Ccr2 (also known as CD192), turned out to be fundamental for the antineoplastic effects of anthracyclinebased chemotherapy in mice. Lymphadenectomy. Mice were subjected to skin decontamination with 10% povidone-iodine (commercial Betadine ® solution) and anesthesia was maintained by continuous mask inhalation of isoflurane flow during surgery. A narrow incision (3 mm) was performed on the thigh, tumordraining lymph nodes (DLNs) were removed using a dissecting forceps, and the incision was eventually closed with sterile skin closure clips. Sham-operated mice were treated with a similar procedure (but were not subjected to lymphadenectomy), and the duration of surgery was standardized between the two groups. After surgery, mice were placed on a heater plate set at 37°C until recovery. 
Results and Discussion
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indicate that the CCL2/CCR2 signaling axis is essential for optimal therapeutic responses to anthracyclines, at least in mice.
Concluding remarks. Taken together, the results presented here indicate that anthracyclinebased chemotherapy promotes the intratumoral accumulation of (presumably blood-borne) myeloid cells, including cells with a DC-like phenotype that mediate antigen presentation.
Immunogenic chemotherapy appears to cause major shifts in the composition of myeloid cell subsets that affect the tumor microenvironment but not lymphoid organs. In addition, available evidence suggests that neoplastic lesions contain all the cellular and humoral elements that are mechanisms (19) . In addition, an autocrine CCL2-dependent signaling pathway has been suggested to promote the survival and mobility of tumor cells (20) , while tumor cell-derived CCL2 has been shown to stimulate metastasis (21) and angiogenesis (22) . In line with these observations, CCL2-or CCR2-targeting agents have been shown to improve the antineoplastic activity of distinct immunotherapeutic regimens (23, 24) as well as the efficacy of gemcitabineand cisplatin-based chemotherapy (25, 26) . Based on these observations, several clinical trials have recently been launched to evaluate the safety and therapeutic potential of CCL2-or CCR2-blocking antibodies, either as standalone therapeutic interventions or combined with conventional chemotherapy, in cancer patients (source http://clinicaltrials.gov).
Here, we investigated the impact of the CCL2/CCR2 system in a rather peculiar context. First, the growth of the tumor models that we chose was unaffected by the absence or presence of Ccl2 or Ccr2 in the host (Figure 4) , implying that none of the aforementioned pro-tumorigenic functions of CCL2/CCR2 operate in this scenario. Second, we focused our attention on the therapeutic immune response elicited by the immunogenic cell death inducer DX. In this experimental setting, the negative impact of CCL2/CCR2 ablation on the therapeutic activity of DX correlated with a reduced intratumoral recruitment of DC-like APCs. It should be noted that the CCL2/CCR2 system mediates the accumulation of myeloid-derived DCs during allergic (27) and autoimmune inflammation (28) , as well as at sites of parasitic (29) 
